Lipid metabolism-related gene signature predicts prognosis and unveils novel anti-tumor drugs in specific type of diffuse large B cell lymphoma
Our results provide the first lipid metabolism-based gene signature for predicting the survival of patients with DLBCL. Furthermore, by determining novel subtypes with our lipid metabolism prognostic model we illustrated that drugs that compromising MYC target genes rather than immune checkpoint inhibitors may be beneficial to DLBCL patients with certain lipid metabolism profiles.
Authors
- Zhiqiang Yi (ORCID: https://orcid.org/0009-0008-7363-4342)
- Yubing Zhu
- Lichao Jiao
- Cancan Wang (ORCID: https://orcid.org/0000-0002-5647-8412)
- Xinxia Li (ORCID: https://orcid.org/0000-0002-0742-8072)
- Huan Zhang (ORCID: https://orcid.org/0000-0001-9339-7999)
- Ran Zhang (ORCID: https://orcid.org/0009-0002-4433-7783)
- Haixia Gao (ORCID: https://orcid.org/0000-0003-0024-2969)
- Meiyu Zhou (ORCID: https://orcid.org/0009-0000-8056-5973)
Institutions
- Xinjiang Medical University (CN)
- Tumor Hospital of Xinjiang Medical University (CN)
- Fuling Center Hospital of Chongqing (CN)
Publication Details
- Journal
- Molecular Medicine
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1186/s10020-024-00988-4
- Citations
- 8
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 2.28
Funders
- Natural Science Foundation of Xinjiang Province
- National Natural Science Foundation of China
- Natural Science Foundation of Xinjiang